Abiopharma

🔍 ZHANG NING (Executive)

Company: Pony AI Inc. (PONY)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 3,667 shares of Class A Ordinary Shares (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 616,206.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,250 shares of Class A Ordinary Shares (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 617,456.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 10,000 shares of Class A Ordinary Shares (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 627,456.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,000 shares of Class A Ordinary Shares (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 647,456.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 17,347 shares of Class A Ordinary Shares at $6.8596 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 630,109.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 3,667 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F8
• Sold 1,250 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,167.00 | transaction_form_type: 4 | Footnotes: F3, F5, F8
• Sold 10,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 56,667.00 | transaction_form_type: 4 | Footnotes: F3, F6, F8
• Sold 20,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 186,668.00 | transaction_form_type: 4 | Footnotes: F3, F7, F8

Footnotes:

• F1: Reflects restricted stock units (RSUs) that vested and settled into Class A ordinary shares.
• F2: Represents the number of shares sold by the Reporting Person pursuant to a mandatory non-discretionary sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of previously reported restricted stock units.
• F3: Each RSU represents the right to receive, upon vesting, one Class A ordinary share.
• F4: This RSU award was granted on May 28, 2021. The vesting schedules are 20% of the total RSU granted shall vest on the first anniversary of April 1, 2021, and the remaining 80% of the total RSU granted are scheduled to vest equally with 5% at the 25th day of the last month of each quarter thereafter.
• F5: This RSU award was granted on May 15, 2023. The vesting schedules are 25% of the total RSU granted shall vest on the first anniversary of April 1, 2023, and the remaining 75% of the total RSU granted are scheduled to vest equally with 6.25% at the 25th day of the last month of each quarter thereafter.
• F6: This RSU award was granted on December 10, 2023. The vesting schedules are 25% of the total RSU granted shall vest on the first anniversary of November 1, 2023, and the remaining 75% of the total RSU granted are scheduled to vest equally with 6.25% at the 25th day of the last month of each quarter thereafter.
• F7: This RSU award was granted on December 4, 2024. The vesting schedules are 25% of the total RSU granted shall vest on the first anniversary of October 31, 2024, and the remaining 75% of the total RSU granted are scheduled to vest equally with 6.25% at the 25th day of the last month of each quarter thereafter.
• F8: This grant does not have an expiration date.